Response of Patients with COPD to Hyperoxia and Normoxia, as Measured by Carbon Dioxide Levels: Study 2

Medical Research Institute of New Zealand0 sites24 target enrollmentOctober 7, 2015

Overview

No summary available.

Registry

who.int

Start Date

October 7, 2015

End Date

May 18, 2017

Last Updated

4 years ago

Study Type

Interventional

Sex

All

Sponsor

•1\. Baseline transcutaneous carbon dioxide of greater than or equal to 60mmHg
•2\. FEV1:FVC ratio \>0\.7
•3\. Age under 16 years
•4\. A diagnosis of bronchiectasis
•5\. Morbid obesity (with a body mass index of greater than or equal to 40\)
•6\. Inability to match FEV1 percentage predicted to a participant that took part in the bronchiectasis oxygen study\*
•7\. Any other condition which, at the investigator’s discretion, is believed may present a safety risk or impact the feasibility of the study or the study results.
•\*This study is designed to allow for comparison of results to a study of similar design in patients with bronchiectasis (ACTRN12615000971538\). Participants will therefore be matched by FEV1 to the participants in the bronchiectasis study (the COPD participant must have an FEV1 percentage predicted within an absolute value of 5% of the FEV1 percentage predicted for the bronchiectasis patient (values inclusive)). An exception to this is for the three bronchiectasis participants that had FEV1 percentage predicted values of 109% or higher, who are to be matched with COPD participants with an FEV1 percent predicted of 80% or over (i.e. participants in the mildest COPD severity category based on FEV1\).